Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

FRAgile X syndrome Clinical trial: Unravelling the science behind this Rare disease in Europe

Objective

CONNECTA Therapeutics is a clinical biotech company developing new treatments for unmet Central Nervous System medical needs associated with neuroplasticity dysfunction, such as Fragile X Syndrome (FXS), a neurodevelopmental rare disease without a cure affecting around 1.8 M patients worldwide. FXS is responsible for 30% of intellectual disability and cognitive deterioration in both males and females, starting at paediatric age and chronically persisting for life, impacting in learning abilities, attention problems, hyperactivity, autism and social impairments. Early intervention in children is crucial to provide the greatest chance of developing a full range of neurodevelopmental skills, and more opportunities for their social inclusion.

Neuroplasticity modulation addressed by the network pharmacology approach is the core of CONNECTA’s technology. Particularly, CTH120, an excellent neuroplasticity modulator, is a new investigational medicinal product designed as an effective cure for both adults and children. This patented and proprietary technology has already succeeded in Phase I clinical trial demonstrating safety, tolerability and pharmacokinetics in humans, and its efficacy will be validated through the FRAXCURE project in the corresponding Phase II clinical trials targeting FXS paediatric and adult patients, including women with childbearing potential.

CONNECTA’s technology expands to other neurodevelopmental diseases, such as Rett syndrome, Down syndrome, and autism spectrum disorder, currently under preclinical testing by CONNECTA. Therefore, the success of the FRAXCURE project will boost the development of medicines for neurodevelopmental diseases for children and adults in Europe. Likewise, FRAXCURE will position CONNECTA as a leading biotech in the already highly successful research-based European pharmaceutical sector while reinforcing the competitiveness of the European Union in a key strategic technological field.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

CONNECTA THERAPEUTICS SL
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 499 999,00
Address
CALLE BALDIRI REIXAC 10
08028 Barcelona
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0